Reduction of blood pressure fluctuations by telmisartan molecule especially in combination with calcium channel antagonist Review article
Article Sidebar
Published:
Dec 31, 2021
Keywords:
arterial hypertension, ABPM, trough/peak ratio, smoothness index, telmisartan, amlodipine, combined therapy
Main Article Content
Abstract
1.28 billion people suffer from hypertension, and its complications cause 10 million deaths each year. Effective antihypertensive therapy is therefore one of the priority tasks of health care. Achieving good BP control depends on many factors, but one of the primary ones is the use of maximally effective therapy in the simplest possible regimen. Amlodipine in combination with telmisartan in the single-pill combination, through its high smoothness index, makes it possible to achieve a satisfactory hypotensive effect lasting 24 h when taken once daily. This combination is also a good alternative for cardiovascularly burdened patients who cannot use angiotensin-converting enzyme inhibitors and for elderly patients, especially after stroke.
Article Details
How to Cite
Łukasiewicz , M., & Mamcarz , A. (2021). Reduction of blood pressure fluctuations by telmisartan molecule especially in combination with calcium channel antagonist. Medycyna Faktow (J EBM), 14(4(53), 410-416. https://doi.org/10.24292/01.MF.0421.9
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1.https://www.who.int https://www.who.int (access: 15.11.2021).
2. Zhou B, Carrillo-Larco RM, Danaei G et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398(10304): 957-80.
3. Raport “NFZ o zdrowiu. Nadciśnienie tętnicze” opublikowany 17.05.2019 r. (access: 15.11.2021).
4. Wytyczne ESC/ESH dotyczące postępowania w nadciśnieniu tętniczym – 2018 rok. Kardiol Pol. 2019; 77(2): 71-159.
5. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1-84.
6. Gajewski P (ed). Interna Szczeklika. Medycyna Praktyczna, Kraków 2020.
7. Stergiou G, Palatini P, Parati G et al; on behalf of the European Society of Hypertension Council and the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021; 39(7): 1293-302.
8. Meredith PA, Eliot HL. FDA guidelines on trough: peak ratios in the evaluation of antihypertensive agents. J Cardiovasc Pharmacol. 1994; 23: 26-30.
9. Zannad F, Matzinger A, Larch J. Trough/peak ratios of once daily angiotensin-converting enzyme inhibitors and calcium antagonists. Am J Hypertens. 1996; 9: 633-43.
10. Elliott HL. Trough: peak ratio and twenty-four-hour blood pressure control. J Hypertens Suppl. 1994; 12(5): 29-33.
11. Parati G, Omboni S, Rizzoni D et al. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens. 1998; 16(11): 1685-91.
12. Verdecchia P, Angeli F, Gattobigio R et al. Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. Am J Hypertens. 2007; 20: 154-61.
13. Mancia G, Bombelli M, Facchetti R et al. Long-term prognostic value of blood pressure variability in the general population: Results of the pressioni arteriose monitorate e loro associazioni study. Hypertension. 2007; 49: 1265-70.
14. Prejbisz A, Kabat M. Zmienność ciśnienia tętniczego – implikacje praktyczne. Kardiologia po Dyplomie. 2012; 11(1): 31-5.
15. Sander D. Kukla C, Klingelhöfer J et al. Relationship Between Circadian Blood Pressure Patterns and Progression of Early Carotid Atherosclerosis. A 3-Year Follow-Up Study. Circulation. 2000; 102: 1536-41.
16. Visseren FLJ, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021; 42(34): 3227-337.
17. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 15471559.
18. https://indeks.mp.pl (access: 15.11.2021).
19. Mitręga K, Kalarus Z. Telmisartan w aspekcie nadciśnienia tętniczego i wysokiego ryzyka sercowo-naczyniowego. Kardiologia i Diabetologia. 2021; 27.
20. Kang WY, Seong SJ, Ohk B et al. Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects. Drug Des Devel Ther. 2018; 12: 545-53.
21. Moen MD. Telmisartan/Amlodipine: Single-Pill Combination in Hypertension. Am J Cardiovasc Drugs. 2010; 10(6): 401-12.
22. Parati G, Schumacher H. Blood pressure variability over 24 h: prognostic implications and treatment perspectives. An assessment using the smoothness index with telmisartan–amlodipine monotherapy and combination. Hypertens Res. 2014; 37: 187-93.
23. Parati G, Schumacher H, Bilo G et al. Evaluating 24-h antihypertensive efficacy by the smoothness index: A meta-analysis of an ambulatory blood pressure monitoring database. J Hypertens. 2010; 28(11): 2177-83.
2. Zhou B, Carrillo-Larco RM, Danaei G et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398(10304): 957-80.
3. Raport “NFZ o zdrowiu. Nadciśnienie tętnicze” opublikowany 17.05.2019 r. (access: 15.11.2021).
4. Wytyczne ESC/ESH dotyczące postępowania w nadciśnieniu tętniczym – 2018 rok. Kardiol Pol. 2019; 77(2): 71-159.
5. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1-84.
6. Gajewski P (ed). Interna Szczeklika. Medycyna Praktyczna, Kraków 2020.
7. Stergiou G, Palatini P, Parati G et al; on behalf of the European Society of Hypertension Council and the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021; 39(7): 1293-302.
8. Meredith PA, Eliot HL. FDA guidelines on trough: peak ratios in the evaluation of antihypertensive agents. J Cardiovasc Pharmacol. 1994; 23: 26-30.
9. Zannad F, Matzinger A, Larch J. Trough/peak ratios of once daily angiotensin-converting enzyme inhibitors and calcium antagonists. Am J Hypertens. 1996; 9: 633-43.
10. Elliott HL. Trough: peak ratio and twenty-four-hour blood pressure control. J Hypertens Suppl. 1994; 12(5): 29-33.
11. Parati G, Omboni S, Rizzoni D et al. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens. 1998; 16(11): 1685-91.
12. Verdecchia P, Angeli F, Gattobigio R et al. Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension. Am J Hypertens. 2007; 20: 154-61.
13. Mancia G, Bombelli M, Facchetti R et al. Long-term prognostic value of blood pressure variability in the general population: Results of the pressioni arteriose monitorate e loro associazioni study. Hypertension. 2007; 49: 1265-70.
14. Prejbisz A, Kabat M. Zmienność ciśnienia tętniczego – implikacje praktyczne. Kardiologia po Dyplomie. 2012; 11(1): 31-5.
15. Sander D. Kukla C, Klingelhöfer J et al. Relationship Between Circadian Blood Pressure Patterns and Progression of Early Carotid Atherosclerosis. A 3-Year Follow-Up Study. Circulation. 2000; 102: 1536-41.
16. Visseren FLJ, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021; 42(34): 3227-337.
17. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358: 15471559.
18. https://indeks.mp.pl (access: 15.11.2021).
19. Mitręga K, Kalarus Z. Telmisartan w aspekcie nadciśnienia tętniczego i wysokiego ryzyka sercowo-naczyniowego. Kardiologia i Diabetologia. 2021; 27.
20. Kang WY, Seong SJ, Ohk B et al. Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects. Drug Des Devel Ther. 2018; 12: 545-53.
21. Moen MD. Telmisartan/Amlodipine: Single-Pill Combination in Hypertension. Am J Cardiovasc Drugs. 2010; 10(6): 401-12.
22. Parati G, Schumacher H. Blood pressure variability over 24 h: prognostic implications and treatment perspectives. An assessment using the smoothness index with telmisartan–amlodipine monotherapy and combination. Hypertens Res. 2014; 37: 187-93.
23. Parati G, Schumacher H, Bilo G et al. Evaluating 24-h antihypertensive efficacy by the smoothness index: A meta-analysis of an ambulatory blood pressure monitoring database. J Hypertens. 2010; 28(11): 2177-83.